Interferon alpha plus ketoprofen or Interferon alpha plus ribavirin in chronic hepatitis C non-responder to Interferon alpha alone: Results of a pilot study

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 8, 1999, Pages 677-684

  Andreone, P ^a   Cursaro, C ^a   Gramenzi, A ^a   Fiorino, S ^a   Di Giammarino, L ^a   Miniere R ^a   D'Errico, A ^a   Grigioni, W F ^a   Gasbarrini, J G ^a   Bernard, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antivirals; HCV infection; Non steroidal anti inflammatory drugs; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALUMINUM MAGNESIUM HYDROXIDE; ANTIVIRUS AGENT; KETOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; RANITIDINE; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; LICHEN PLANUS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KETOPROFEN; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; RNA, VIRAL;

EID: 33746233587     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Seminars in liver disease 1995;15:82-91.
2. Di Bisceglie AM, Conjeeveram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995;123:897-903.
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk OS, Ideo G, et al. Randomised trial of Interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
5. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998-.339:1493-9.
6. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouvver JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-6.
7. Andreone P, Gramenzi A, Cursaro C, Felline F, Gasbarrini G, Bemardi M. Interaction between non steroidal antiinflammatory drugs and interferon-a system: mechanisms and basis for the clinical use in the treatment of chronic viral hepatitis. In: Dianzani F, Gentilini P, editors. New trends in hepatology. Dordrecht: Kluwer Academic Publishers; 1996. p. 306-14.
8. Andreone P, Cursaro C, Gramenzi A, Miniero R, Bemardi M, Gasbarrini G. Interferon-a plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFNct course: results of a pilot study. Int Hepatol Commun 1996;5:151-9.
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;l:431-5.
10. Lee CH, Cheng C, Wang J, Lumeng L. Identification of hepatitis C viruses with a nonconserved sequence of the 5' untranslated region. J Clin Microbiol 1992;30:1602-4.
11. Hannigan GE, Williams BRG. Signal transduction by interferona through arachidonic acid metabolism. Science 1991;251:204-7.
12. Giambartolomei S, Artini M, Almerighi C, Moavero SM, Levrero M, Balsano C. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Hepatology 1999;30:510-6.
13. Andreone P, Cursaro C, Gasbarrini G. Interferon-a increases prostaglandin E2 production by cultured-liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993;19:228-31.
14. Andreone P, Cursaro C, Gramenzi'jA, Buzzi A, Minière R, Bemardi M, et al. Indomethacin increases 2',5'-oligoadenylate synthetase by cultured liver tissue of patients with HCV chronic active hepatitis. Int Hepatol Comm 1994;2:289-94.
15. Andreone P, Cursaro C, Gramenzi A, Buzzi A, Minière R, Sprovieri G, et al. Indomethacin enhances 2',5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis. J Hepatol 1994;21:984-8.
16. Andreone P, Cursaro C, Gramenzi A, Margotti M, Di Giammarino L, Fiorino S, et al. Modulation of Thl/Th2 cytokine profile and antiviral response by interferon a (IFNa) and non steroidal antiinflammatory drugs (NSAIDs) in hepatitis C virus (HCV) infection. Hepatology 1997;26:410A.
17. Baskin G. Interferon signalling through arachidonic acid dependent pathway: a clue to adjuvant therapy for chronic viral hepatitis? Hepatology 1991; 14:392-4.
18. Anderson FH, Zeng L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interferonresistant chronic hepatitis C. Can J Gastroenterol 1997;! 11:294-7.
19. Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998;27:862-7.
20. Munoz A, Levi D, Podestà A, Bartellini MA, Gonzales J, Monti Gorin J, et al. Interferon associated to ketoprofen vs interferon alone in the treatment of HCV chronic hepatitis. Preliminary results of a randomized study. Hepatology 1997;26:568A.
21. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991;87:1916-24.
22. n Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997:26:473-7.